Free Trial
NASDAQ:MLTX

MoonLake Immunotherapeutics Q1 2025 Earnings Report

MoonLake Immunotherapeutics logo
$18.19 0.00 (0.00%)
Closing price 05/22/2026 04:00 PM Eastern
Extended Trading
$18.15 -0.04 (-0.24%)
As of 05/22/2026 07:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

MoonLake Immunotherapeutics EPS Results

Actual EPS
-$0.63
Consensus EPS
-$0.76
Beat/Miss
Beat by +$0.13
One Year Ago EPS
-$0.22

MoonLake Immunotherapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

MoonLake Immunotherapeutics Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

MoonLake Immunotherapeutics' Q2 2026 earnings is estimated for Tuesday, August 4, 2026, based on past reporting schedules, with a conference call scheduled on Wednesday, August 5, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

MoonLake Immunotherapeutics Earnings Headlines

MoonLake Immunotherapeutics Class A MLTX
Musk's shopping list: batteries ✓ solar ✓ data ✓ power ___
Elon Musk has a clear pattern: when a supplier becomes mission-critical, he acquires it. He bought SolarCity for $2.6 billion and Twitter for $44 billion. Now one small company makes the equipment his Colossus supercomputer - a million GPUs consuming nearly $1 billion a month in power - cannot run without. Analyst Dylan Jovine has identified the name and ticker. For investors who own shares before a potential move, the math could be significant.tc pixel
See More MoonLake Immunotherapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like MoonLake Immunotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MoonLake Immunotherapeutics and other key companies, straight to your email.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics (NASDAQ:MLTX), a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

View MoonLake Immunotherapeutics Profile